Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2001 June; 2(2): 14–21.
Published online 2001 April 2. doi:  10.1208/pt020206
PMCID: PMC2750472

Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets


The effect of the concentration of hydrophilic (hydroxypropyl methylcellulose [HPMC]) and hydrophobic (hydrogenated castor oil [HCO]) products, fillers (lactose and dibasic calcium phosphate), and buffers (sodium bicarbonate, calcium carbonate, and sodium citrate) on naproxen release rate was studied. Matrix tablets were prepared by double compression, andIn vitro dissolution tests were performed. The dissolution results showed that an increased amount of HPMC or hydrogenated castor oil resulted in reduced drug release. The inclusion of buffers in the HPMC matrix tablets enhanced naproxen release. For HCO tablets, only sodium bicarbonate enhanced naproxen release. The presence of lactose on HPMC matrix tablets did not show a significantly different result from that obtained with the formulation containing dibasic calcium phosphate as a filler. However, for the tablets containing HCO, the presence of lactose significantly enhanced the naproxen release rate. The matrix-forming materials in this study were suitable for use in sustained-release tablets containing naproxen. The drug release can be modulated by adding suitable amounts of diluents and buffers.

Keywords: Naproxen, Sustained-release, Hydrophilic matrix, Lipidic matrix

Full Text

The Full Text of this article is available as a PDF (154K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Todd PA, Clissold SP. Naproxen: a reappraisal of its pharmacology, and use in rheumatic diseases and pain states. Drugs. 1990;40:91–137. [PubMed]
2. Pather S, Russell I, Syce J, Neau S. Sustained release theophylline tablets by direct compression, Part 1: formulation andIn vitro testing. Int J Pharm. 1998;164:1–10. doi: 10.1016/S0378-5173(97)00348-7. [Cross Ref]
3. Salsa T, Veiga F, Pina mE. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:929–938. doi: 10.3109/03639049709148697. [Cross Ref]
4. Kibbe A. Handbook of Pharmaceutical Excipients. Washington: American Pharmaceutical Association and The Pharmaceutical Society of Great Britain; 1986. pp. 49–50.
5. Lachman L, Lieberman HA, Kanig JL. Pharmaceutical Dosage Forms-Tablets. 2nd ed. New York: marcel Dekker Inc; 1989. pp. 13–13.
6. Zecchi V, Rodriguez L, Tartarini A, Chiarini A, Valenti P. In vitro absorption studies on naproxen and its sodium and piperazine salts. Pharm Acta Helv. 1984;59:91–94.
7. US Pharmacopoeia XXIII. Rockville, MD: US Pharmacopeial Convention; 1995:1054.
8. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149. doi: 10.1002/jps.2600521210. [PubMed] [Cross Ref]
9. European Pharmacopeia. 3rd ed. Council of Europe, Strasbourg; 1997:133–135.
10. Morgan S, Preston CL, Timmins P, melia CD. An investigation into the effect of citrate buffering on pH-dependent drug release, hydration and gel layer growth in HPMC matrices. Proceedings of the 18th Pharmaceutical Technology Conference. 1999;2:24–32.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists